Drug intelligence / Profile preview

YYC405-T

Development stage: Phase 3
Lead developer: Yooyoung Pharmaceutical
Administration: Oral

Overview

YYC405-T is an investigational drug developed by Yooyoung Pharmaceutical for the treatment of type 2 diabetes mellitus. It is currently in clinical development and has been studied in combination with metformin and dapagliflozin for patients with inadequate glycemic control. The precise mechanism of action for YYC405-T remains unknown at this time[1][2][3][4]. Clinical trials have evaluated its efficacy and safety as an add-on therapy to standard antidiabetic agents.

Beyond the preview

Go deeper on YYC405-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YYC405-T.

Explore the full profile